What is the recommended treatment for immune thrombocytopenia (ITP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

ITP Treatment

For newly diagnosed adult ITP requiring treatment (platelets <30 × 10⁹/L), start with corticosteroids as first-line therapy, preferably longer courses over shorter courses, and add IVIg (1 g/kg) when rapid platelet increase is needed. 1

Initial Diagnosis and Testing

Before initiating treatment, test all patients for:

  • HCV and HIV (grade 1B) 1
  • H. pylori if positive testing would lead to eradication therapy (grade 2C) 1

Bone marrow examination is NOT necessary in patients presenting with typical ITP, regardless of age (grade 2C). 1

First-Line Treatment for Adults

Treatment Threshold

Initiate treatment when platelet count is <30 × 10⁹/L (grade 2C). 1

Preferred Initial Regimen

Longer courses of corticosteroids are preferred over shorter courses or IVIg alone (grade 2B). 1

Add IVIg (1 g/kg as single dose) with corticosteroids when more rapid platelet increase is required (grade 2B). This dose may be repeated if necessary. 1

Alternative First-Line Options

  • IVIg or anti-D (in Rh-positive, non-splenectomized patients) if corticosteroids are contraindicated (grade 2C) 1

Novel Approach (2026 Update)

The most recent ASH 2026 guidelines now suggest combination therapy with rituximab plus corticosteroids OR thrombopoietic agent plus corticosteroids rather than corticosteroids alone for initial therapy (conditional recommendation). 2 This represents a significant shift from traditional monotherapy approaches.

Second-Line Treatment After Corticosteroid Failure

The treatment algorithm depends on duration of ITP and patient priorities:

For ITP <12 Months Duration

Thrombopoietin receptor agonists (TPO-RAs) are conditionally recommended over rituximab, primarily due to greater durability of response with ongoing use. 3

However, rituximab may be preferable for patients who:

  • Place high value on avoiding long-term medication
  • Cannot afford TPO-RAs
  • Have limited access to these agents

For ITP >12 Months Duration (Chronic ITP)

Three viable options exist: splenectomy, TPO-RAs, and rituximab. The choice depends on patient priorities:

If Patient Wants to Avoid Surgery:

TPO-RAs are conditionally recommended over rituximab (grade 2C) due to greater durability of response. 3

The 2026 ASH guidelines provide strong recommendation for TPO-RAs and conditional recommendation for rituximab in patients who failed first-line corticosteroids. 2

If Patient Wants to Avoid Long-Term Medication:

Rituximab is conditionally recommended over splenectomy despite splenectomy having higher durable response rates, because of operative risks, irreversible nature, and long-term risks of infection and thrombosis. 3

If Patient Prioritizes Durable Response:

Either TPO-RAs or splenectomy (conditional recommendation for both), recognizing that cost, accessibility, and individual preferences vary substantially. 3

Specific Second-Line Recommendations

Splenectomy is recommended (grade 1B) for patients who have failed corticosteroid therapy. 1

TPO-RAs are recommended (grade 1B) for patients at risk of bleeding who:

  • Relapse after splenectomy, OR
  • Have contraindication to splenectomy AND have failed at least one other therapy 1

Rituximab may be considered (grade 2C) for patients at risk of bleeding who have failed one line of therapy. 1

Special Populations

Pregnancy

Corticosteroids or IVIg for pregnant patients requiring treatment (grade 1C). 1

Mode of delivery should be based on obstetric indications, not platelet count (grade 2C). 1

HIV-Associated ITP

Treat HIV infection with antiviral therapy first before other ITP treatments unless clinically significant bleeding complications exist (grade 1A). 1

If ITP treatment needed: corticosteroids, IVIg, or anti-D initially, then splenectomy for symptomatic patients who fail (grade 2C). 1

HCV-Associated ITP

Antiviral therapy should be considered in absence of contraindications (grade 2C), but monitor platelets closely as interferon may worsen thrombocytopenia. 1

If ITP treatment required: IVIg as initial treatment (grade 2C). 1

H. pylori-Associated ITP

Eradication therapy should be administered in patients found to have H. pylori infection (grade 1B). 1

Post-Splenectomy Management

Do NOT treat asymptomatic patients after splenectomy with platelet counts >30 × 10⁹/L (grade 1C). 1

Both laparoscopic and open splenectomy offer similar efficacy for medically suitable patients (grade 1C). 1

Critical Pitfalls to Avoid

  1. Delaying splenectomy at least 12 months unless severe disease unresponsive to other measures (grade 2C) 1, as spontaneous remission may occur in the first year

  2. Not using anti-D in children with decreased hemoglobin from bleeding or evidence of autoimmune hemolysis (grade 1C) 1

  3. Over-treating asymptomatic patients with platelet counts >30 × 10⁹/L

  4. Failing to reassess treatment decisions regularly, as patient preferences and disease duration influence optimal therapy selection 3

References

Related Questions

What is the recommended treatment for an adult with newly diagnosed immune thrombocytopenia (ITP) presenting with platelet count below 30 × 10⁹/L or bleeding?
What is the recommended management for a patient with chronic immune thrombocytopenia (ITP) persisting longer than 12 months?
What is the appropriate approach to manage a 50-year-old male with immune-mediated thrombocytopenia on prednisolone who presents with 7 days of loose stools, urge to defecate, 5 days of generalized weakness, stable vital signs, and a platelet count of 122 ×10³/µL?
What are the current recommended treatment options for an adult with chronic immune thrombocytopenia (ITP) refractory to a brief course of corticosteroids?
What is the appropriate workup for thrombocytopenia and when are corticosteroids beneficial versus ineffective?
A female patient with a recent mandibular fracture who has been unable to brush her teeth for three weeks now presents with a brown-coated tongue; what is the appropriate next management?
What is the recommended evaluation and management for suspected pelvi‑ureteric junction (PUJ) obstruction?
Can generalized anxiety disorder coexist with mixed anxiety‑depressive disorder?
What are the appropriate dosing, contraindications, precautions, and monitoring recommendations for triazolam in short‑term treatment of insomnia?
How should a patient with Clostridioides difficile infection who is NPO be treated?
In a 74-year-old male with pneumonia who has an elevated creatine kinase, what is the appropriate evaluation and management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.